Physician profile
Rosalyn Lien
NPI 1851943401
$2,116.56
in general payments reported to CMS, 2019-2025
17 companies · $512 in 2025
The $512 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.21 · 2021: $239 · 2022: $34.90 · 2023: $813 · 2024: $504 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.44 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $394.03 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $203.37 | 2023-2025 | Simbrinza, Rhopressa, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $152.05 | 2019-2022 | |
| Astellas Pharma US INC | $144.48 | 2024-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $130.18 | 2023-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $119.32 | 2021 | |
| Dompe US, INC. | $75.60 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $68.24 | 2024-2025 | Xdemvy |
| Amgen INC. | $49.78 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $49.00 | 2023-2024 | Tecnis Iol, One Series Ultra |
| Rxsight INC | $44.53 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $30.35 | 2023 | Tyrvaya |
| Thea Pharma INC. | $24.25 | 2023 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $23.73 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $22.57 | 2025 | Syfovre |
| Allergan, INC. | $15.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalyn Lien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.